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PreviewsIt seems likely that additional cells and
molecules contribute to the support of
HSCs and progenitor cells. For example,
marrow failure results from targeting
the gp130 cytokine receptor component
on endothelial cells (Yao et al., 2005).
Regardless, the new findings suggest
how specialized subsets of multipotent
stromal cells are developmentally related
and perhaps functionally linked. Endo-
crine and neural signals presumably
convert them to cell types that maintain
stem cell integrity, influence lineage
choice decisions, or suppress hemato-
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In this issue of Immunity, Pe´rez de Diego et al. (2010) report a primary human immune deficiency involving
a TRAF protein and show that human immunity to the virus HSV-1 is critically dependent on TRAF3.Tumor necrosis factor (TNF) receptor
associated factors (TRAFs) are multifunc-
tional intracellular proteins that recruit
and activate protein kinases in immune
signaling pathways. The function of
many TRAF proteins has been particularly
well established in TNF receptor family
signaling in B and T lymphocytes and in
pattern recognition receptor (PRR) sig-
naling in antigen-presenting cells, mainly
through the use of gene-deleted mice.
For example, TRAF6 has been shown to
be critical for signaling by two PRR fami-
lies, namely the Toll-like receptors (TLRs)
and RIG-I-like receptors (RLRs), where it
controls activation of the transcription
factor NF-kB, leading to the production
of proinflammatory cytokines. However,
the function of TRAF3 remained enigmatic
until 2006 because Traf3/ mice die
shortly after birth (Xu et al., 1996). In that
year, two studies used Traf3/ myeloid
cells to show that TRAF3 was essential
for induction of type I interferons (IFNs)in response to all the murine antiviral
nucleic acid sensing TLRs (TLR3, -7, -9)
and also for TLR-independent type I IFN
induction, whereas in contrast to TRAF6,
there was no positive role for TRAF3
in NF-kB activation (Oganesyan et al.,
2006; Ha¨cker et al., 2006). For TLRs,
TRAF3 acted downstream of the TLR
signaling proteins TRIF (for TLR3) and
MyD88 and IRAK-4 (for TLR7 and -9),
whereas TRAF3 acted in the RLRpathway
downstream of the adaptor MAVS (Saha
et al., 2006). Murine TRAF3 was also
shown to negatively regulate the nonca-
nonical NF-kB pathway in B cells, which
involves processing of NF-kB p100 into
NF-kB p52, and indeed, constitutive acti-
vation of this pathway explained the post-
natal lethality seen in Traf3/ mice (He
et al., 2006). Thus, in mice, using Traf3/
cells, TRAF3 was assigned a positive role
in type I IFN induction by PRRs and
a negative regulatory role in B cells.
However, the role of TRAF3 in hostdefense in vivo and in immunity to infec-
tion was untested because of the lack
of viable Traf3/ mice. Furthermore,
nothing was known about the role of
TRAF3 (or indeed any TRAF) in human
host defense.
In this issue of Immunity, Pe´rez de
Diego et al. (2010) now provide insight
into the immunological role of TRAF3 in
host defense in vivo. Moreover, they do
so in the human system, because they
describe TRAF3 deficiency as a genetic
susceptibility to herpes simplex virus-1
(HSV-1) encephalitis (HSE), a severe
infection of the human central nervous
system (CNS). Not only does this study
provide real evidence for a role for
TRAF3 in human immune responses, it
also represents a demonstration of a
primary immune deficiency involving a
TRAF protein. Evidence is presented
for an autosomal dominant TRAF3 defi-
ciency in a young adult with a history of
HSE in childhood in that a single pointptember 24, 2010 ª2010 Elsevier Inc. 293
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Figure 1. Role for TRAF3 in Human Immune Signaling Pathways
Using ex vivo cells from a patient with an autosomal-dominant TRAF3 deficiency, the contribution of TRAF3 to some human immune signaling pathways has been
revealed. Functional TRAF3was required for normal TLR3-, TLR7-, and RIG-I-mediated gene induction, whereas in B cells, TRAF3 has both positive and negative
roles in gene induction by TNFRs (CD40 and BAFF-R). As was shown for murine B cells, TRAF3 prevents constitutive processing of NF-kB p100 into NF-kB p52 in
human cells. However, in contrast to murine studies, which show a role for TRAF3 in IRF3 and not NF-kB p65 activation in human TLR3 signaling, TRAF3 has
a major role (solid arrow) in p65 activation but more minor role (dashed arrow) in IRF3 activation (left panel). Genetic evidence suggests that the TLR3 pathway
depicted on the left primarily accounts for the requirement for TRAF3 in immunity against primary infection by HSV-1 in the CNS.
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Previewsmutation (R118W) of one TRAF3 allele led
to a loss-of-function, dominant-negative
phenotype, leading to greatly reduced
expression of TRAF3 protein.
This TRAF3 study comes on the back
of previous studies from the Casanova
group where they have examined the clin-
ical genetics of infectious diseases and
identified primary immune deficiencies
that have allowed an important com-
parison between the role of TLRs and their
signaling components in experimental
infections in animal models and in
humans in natura (Quintana-Murci et al.,
2007). Apart from the obvious importance
of working in humans, these studies in
a natural ecosystem governed by natural
selection have the advantage that they
dissect natural, and not experimentally-
induced, phenotypes relating to infection.
They also allow the testing of paradigms
developed in murine models. One such
paradigm, that TLRs are critical in the
host response to a broad range of infec-
tions, has been questioned by these
studies (Quintana-Murci et al., 2007).
This is because patients with deficiencies
in TLRs or their signaling components
seem susceptible to a much narrower
range of infections that would be pre-294 Immunity 33, September 24, 2010 ª2010dicted by murine models, even though
cells derived from such patients show
the expected impaired responses to
multiple pathogens. Thus, IRAK-4- or
MyD88-deficient patients suffer from
pyogenic bacterial infections (such as
pneumococcal disease) but seem to
have normal resistance to all other
microbes (Quintana-Murci et al., 2007;
von Bernuth et al., 2008), whereas TLR3-
deficient patients, in an identical pheno-
type to that reported here for TRAF3
deficiency, show a selective predisposi-
tion to HSE (Zhang et al., 2007).
The functional defect in TRAF3
observed here was because of reduced,
but not completely depleted, amounts
of TRAF3 protein in cells, because the
mutant R118W protein exerted a destabi-
lizing effect on normal TRAF3 protein
expressed from the other allele. Evidence
suggests that the R118W protein destabi-
lizes TRAF3 trimer formation, whichwould
explain the loss of function because
activation of TRAFs requires their oligo-
merization.
The observation that TRAF3 deficiency
in humans causes HSE specifically was
not predicted by any of the murine work
to date. The availability of cells expressingElsevier Inc.the TRAF3 R118W mutant from the
patient allowed a comprehensive study
of the role of human TRAF3 in various
PRR and B cell signaling pathways.
R118W fibroblasts failed to produce
the cytokines IFN-b, IFN-l, or IL-6 in
response to TLR3 stimulation by either
double-stranded RNA or the neurotrophic
vesicular stomatitis virus (VSV), and in
contrast to murine signaling pathways,
NF-kB was strongly impaired, while IRF3
activation was only mildy affected (Fig-
ure 1). Furthermore, R118W fibroblasts
failed to control VSV replication as effec-
tively as control cells. These defects
were all complemented by transfection
of wild-type TRAF3 into cells. The defects
in PRR signaling were not confined to the
TLR3 pathway, because gene induction
by TLR7 in monocytes or by RIG-I in
fibroblasts (Figure 1) was also inhibited
in mutant cells. The induction of IFN-b
and IFN-l in response to viral infection
of R118W fibroblasts was similarly sup-
pressed. Surprisingly then, IFN-a induc-
tion in response to a range of viruses,
including HSV-1, was normal in R118W
peripheral blood mononuclear cells
(PBMCs), suggesting that residual levels
of TRAF3 are sufficient for IFN responses
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Previewsin PBMCs or that other proteins may
compensate for the reduced TRAF3 in
these cells. Thus, similar to the murine
data, human TRAF3 is important for IFN
induction, although the particular tran-
scription factors regulated by TRAF3
differ in humans, asmight the cell-specific
role of TRAF3 in virus-induced IFN.
Turning to R118W B cells, TNFR path-
ways (CD40 and BAFF-R) were affected
both positively and negatively by TRAF3
loss of function. For CD40, TRAF3 is
a positive regulator, resulting in the
impaired production of some cytokines
in R118W cells, whereas for the B cell
activation factor receptor (BAFF-R)
pathway, TRAF3 is a negative regulator
(Figure 1). Similar to the situation inmurine
B cells, the noncanonical NF-kB pathway
involving p100 processing into p52 was
constitutively active because of impaired
TRAF3 function (Figure 1). However, it is
likely that the overall effects of impaired
TRAF3 function on B cell signaling are
more minor than that on the PRR path-
ways because complete defects in CD40
or BAFF-R signaling do have clinical
consequences in terms of B cell expan-
sion and function, whereas no such
consequences seemed apparent for the
TRAF3-deficient patient studied here.
In terms of human TRAF3 function,
several questions remain. Although the
authors argue that the role of TRAF3 in
protection against HSE is because of
TRAF3’s involvement in the TLR3 path-way (Figure 1), it is possible that there
are alternative explanations for this.
Certainly the TRAF3 deficiency mimics
the previously reported TLR3 deficiency
in terms of susceptibility to HSE (Zhang
et al., 2007), and indeed, TLR3 is a
PRR particularly expressed in the CNS.
However, HSV-1 has been shown to be
sensed by multiple PRRs in mice, and
thus, an alternative explanation for the
essential role of TRAF3 in HSE protection
in humans could be because of TLR3-
independent roles for TRAF3 in PRR
signaling (for example, Figure 1C). Then,
TLR3 and TRAF3 would both be indepen-
dently necessary, but not sufficient, for
protection against HSE. A further but
related issue is, as in the case for TLR3,
the narrow disease susceptibility arising
from TRAF3 deficiency, especially given
the prediction from murine and in vitro
studies that TRAF3 is utilized by most
PRRs for IFN induction. One explanation
for this is that in humans, the function of
TRAF3 is redundant except for TLR3
signaling in the CNS and that TLR3 is
redundant in viral sensing except for neu-
rotrophic viruses such as HSV-1. The
exact mechanism by which TRAF3 (and
TLR3) exert a protective effect against
HSV-1 infection in the CNS is also
unknown and requires further study.
Further work will also be required to
confirm that human TRAF3 is more impor-
tant for NF-kB activation than for IRF3
activation, as this would be a crucialImmunity 33, Semouse-human difference. Overall, this
study demonstrates the importance of
TRAF3 for human host defense and
provides mechanistic insights into how
this important protein regulates human
immune signaling.
REFERENCES
Ha¨cker, H., Redecke, V., Blagoev, B., Kratchmar-
ova, I., Hsu, L.-C., Wang, G.C., Kamps, M.P.,
Raz, E., Wagner, H., Ha¨cker, G., et al. (2006).
Nature 439, 204–207.
He, J.Q., Zarnegar, B., Oganesyan, G., Saha, S.K.,
Yamazaki, S., Doyle, S.E., Dempsey, P.W., and
Cheng, G. (2006). J. Exp. Med. 203, 2413–2418.
Oganesyan, G., Saha, S.K., Guo, B., He, J.Q.,
Shahangian, A., Zarnegar, B., Perry, A., and
Cheng, G. (2006). Nature 439, 208–211.
Pe´rez de Diego, R., Sancho-Shimizu, V., Lorenzo,
L., Puel, A., Plancoulaine, S., Picard, C., Herman,
M., Cardon, A., Durandy, A., Bustamante, J.,
et al. (2010). Immunity 33, this issue, 400–411.
Quintana-Murci, L., Alcaı¨s, A., Abel, L., and
Casanova, J.-L. (2007). Nature 8, 1165–1171.
Saha, S.K., Pietras, E.M., He, J.Q., Kang, J.R., Liu,
S.-Y., Oganesyan, G., Shahangian, A., Zarnegar,
B., Shiba, T.L., Wang, Y., and Cheng, G. (2006).
EMBO J. 25, 3257–3263.
von Bernuth, H., Picard, C., Jin, Z., Pankla, R.,
Xiao, H., Ku, C.L., Chrabieh, M., Mustapha, I.B.,
Ghandil, P., Camcioglu, Y., et al. (2008). Science
321, 691–696.
Xu, Y., Cheng, G., and Baltimore, D. (1996).
Immunity 5, 407–415.
Zhang, S.Y., Jouanguy, E., Ugolini, S., Smahi, A.,
Elain, G., Romero, P., Segal, D., Sancho-Shimizu,
V., Lorenzo, L., and Puel, A. (2007). Science 317,
1522–1527.ptember 24, 2010 ª2010 Elsevier Inc. 295
